Clinical Trials - June 3, 2020
Positive trial results from AstraZeneca
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal cancer and liver cancer. The Phase III ADAURA trial showed for example that treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by c. 80%. Tagrisso “The momentous […]
Pharma Business - May 25, 2020
New approval for Lynparza in the US
AstraZeneca and MSD have announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III PROfound trial, which were published in The New England Journal of Medicine. […]
Pharma Business - May 18, 2020
AstraZeneca’s Aerosphere approved in China for COPD patients
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The approval by the National Medical Products Administration (NMPA)was based on positive results from the Phase III PINNACLE 4 trial1 in which Bevespi Aerosphere demonstrated […]
Pharma Business - May 13, 2020
AstraZeneca’s Enhertu granted breakthrough therapy designation in the US
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab. The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development […]
Clinical Trials - May 6, 2020
AstraZeneca and the University of Oxford announce agreement for COVID-19 vaccine
AstraZeneca and the University of Oxford have announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at […]
Collaboration - April 27, 2020
AstraZeneca collaborates with WWF on water stewardship
AstraZeneca has announced a new collaboration with the World Wide Fund for Nature (WWF) Sweden. The twelve-month partnership will focus on identifying opportunities to improve the company’s approach and strategy towards water stewardship and identify initial opportunities to engage in on-the-ground water projects in the river basins where AstraZeneca operates. Science-Based Targets for Water Together […]
